Reviewed by Bobeck S. Modjtahedi, MD

Investigators from Kaiser Permanente Southern California’s Eye Monitoring Center and Department of Research and Evaluation reported the accuracy of a new tool for predicting the 3-year risk of vision-threatening diabetic retinopathy (VTDR) in patients with type 2 diabetes mellitus.

Speaking at the American Society of Retinal Specialists 2022 annual meeting at the Jacob K. Javits Convention Center in New York, Bobeck Modjtahedi, MD, lead author of the study, pointed out that the future risk of the development of new-onset VTDR, diabetic macular edema (DME), and proliferative DR (PDR) can be predicted using the patient’s retinopathy status and hemoglobin A1c value.

According to Modjtahedi, the researchers believe that this tool will prove to be valuable for more targeted monitoring and treatment intervention into patients with type 2 diabetes with the goal of preventing vision loss.

Retrospective cohort study

The research included patients who were aged 18 and older and had undergone screening for DR from 2012 to 2015. The treatment-naïve patients also had to have no history of DME, PDR, or other macular exudative or retinal vascular disease.

The investigators identified 215,154 patients who satisfied the study inclusion criteria. More than 20 potential predictors of VTDR, defined as DME and/or PDR based on diagnosis codes with a concurrent retinal intervention, were examined for inclusion in the model.

Prediction models for the 3-year risks of VTDR, DME, and PDR were developed and validated.

Prediction model performance

The 215,154 patients were a mean age of 60 years and 54% female, about a third were Caucasian, and 40% Hispanic.

The final models developed were able to predict future VTDR, DME, and PDR using DR status and hemoglobin A1c.

“Although other variables such as renal function and duration of diabetes were significantly associated with the outcomes, including them did not improve the c-index sufficiently to be included in the final model,” Modjtahedi explained. “The average c-index pooled over 50 validation datasets, and 10 testing datasets were ≥ 92% and 94% for each outcome at 3 years, respectively.”

A risk calculator is avialable at https:.//vtdrtest.kp-scalresearch.org/.

Based on their results, the authors concluded that the future risk of development of new-onset VTDR, DME, and PDR can be predicted accurately using a patient’s retinopathy status and hemoglobin A1c level.

Modjtahedi also pointed out that these models may be used to assist patient education and management, including determining follow-up schedules and identifying patients who may benefit from more rigorous diabetes control and/or prophylactic ophthalmic treatment.

Bobeck S. Modjtahedi, MD

Modjtahedit email: bobmodj@gmail.com

Modjtahedi has no financial disclosures related to this content.